
    
      This is a parallel-group, double-blind, randomized controlled crossover trial with a 1:1
      randomization. There are two treatment periods of 4 weeks and a two-week off treatment
      washout period. Treatment periods are DER (dalfampridine ER) followed by placebo (group A)
      and placebo followed by DER (group B), respectively. All dosages will be administered twice a
      week. Purpose of the study is to see if using the study drug(dalfampridine Er) for a short
      period of time will improve the way subjects with multiple sclerosis (MS) walk.
    
  